Aa
Inovio Biomedical Corp Hepatitis C Virus DNA Vaccine
Inovio Biomedical Corp Hepatitis C Virus DNA Vaccine
IP: 72.91.158.146
Posted on March 17, 2008 at 04:35:45 PM by Patient
INOVIO BIOMEDICAL CORP
Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
3/17/2008
SAN DIEGO, Mar 17, 2008 (BUSINESS WIRE) --
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden, has reported preliminary results from the first patient to complete treatment with Tripep's therapeutic hepatitis C virus (HCV) vaccine, ChronVac-C(R), which was delivered using Inovio's electroporation-based DNA delivery system. In this phase I/II clinical study, the treatment has so far been safe and tolerable. Samples taken before, during and after treatment showed that before vaccination the patient did not have a detectable cell-mediated immune response against HCV but such an immune response became detectable after treatment was completed. Inovio's electroporation delivery technology is intended to enhance the potency of DNA-based immunotherapies, including DNA vaccines, against cancers and infectious diseases.
ChronVac-C(R) is a therapeutic DNA vaccine being given to individuals already infected with hepatitis C virus with the aim to clear the infection by boosting a cell-mediated immune response against the virus. It is known that patients who spontaneously clear their infection have also developed this type of immune response.
This clinical study is being conducted at the Infectious Disease Clinic and Center for Gastroenterology at the Karolinska University Hospital in Huddinge and Solna (Sweden), respectively. Intended enrollment is 12 patients divided into three dose groups with increasing doses of ChronVac-C(R). Each patient receives four ChronVac-C(R) vaccinations one month apart. After the last vaccination, patients are followed for another six months. The study's main purpose is to assess safety. It is also testing whether the treatment boosts the immune response to HCV and its effect on virus replication in the liver. If the patient is completely virus-free six months after completing treatment, he/she will be considered cured. This first reported data was from the first patient in the lowest dose group. Five patients have been treated and no unexpected side effects have been observed.
"We are pleased that this first infectious disease DNA vaccine to be delivered in humans using electroporation-based DNA delivery has provided initial evidence of being safe and inducing a cell mediated immune response against the hepatitis C virus," stated Avtar Dhillon, MD, Inovio's president and CEO. "We look forward to seeing additional data, particularly from the higher dose groups, relating to this potential treatment to a pervasive and difficult-to-treat disease."
Ron
IP: 72.91.158.146
Posted on March 17, 2008 at 04:35:45 PM by Patient
INOVIO BIOMEDICAL CORP
Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
3/17/2008
SAN DIEGO, Mar 17, 2008 (BUSINESS WIRE) --
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden, has reported preliminary results from the first patient to complete treatment with Tripep's therapeutic hepatitis C virus (HCV) vaccine, ChronVac-C(R), which was delivered using Inovio's electroporation-based DNA delivery system. In this phase I/II clinical study, the treatment has so far been safe and tolerable. Samples taken before, during and after treatment showed that before vaccination the patient did not have a detectable cell-mediated immune response against HCV but such an immune response became detectable after treatment was completed. Inovio's electroporation delivery technology is intended to enhance the potency of DNA-based immunotherapies, including DNA vaccines, against cancers and infectious diseases.
ChronVac-C(R) is a therapeutic DNA vaccine being given to individuals already infected with hepatitis C virus with the aim to clear the infection by boosting a cell-mediated immune response against the virus. It is known that patients who spontaneously clear their infection have also developed this type of immune response.
This clinical study is being conducted at the Infectious Disease Clinic and Center for Gastroenterology at the Karolinska University Hospital in Huddinge and Solna (Sweden), respectively. Intended enrollment is 12 patients divided into three dose groups with increasing doses of ChronVac-C(R). Each patient receives four ChronVac-C(R) vaccinations one month apart. After the last vaccination, patients are followed for another six months. The study's main purpose is to assess safety. It is also testing whether the treatment boosts the immune response to HCV and its effect on virus replication in the liver. If the patient is completely virus-free six months after completing treatment, he/she will be considered cured. This first reported data was from the first patient in the lowest dose group. Five patients have been treated and no unexpected side effects have been observed.
"We are pleased that this first infectious disease DNA vaccine to be delivered in humans using electroporation-based DNA delivery has provided initial evidence of being safe and inducing a cell mediated immune response against the hepatitis C virus," stated Avtar Dhillon, MD, Inovio's president and CEO. "We look forward to seeing additional data, particularly from the higher dose groups, relating to this potential treatment to a pervasive and difficult-to-treat disease."
Ron
http://en.wikipedia.org/wiki/Electroporation
"...a significant increase in the electrical conductivity and permeability of the cell plasma membrane caused by an externally applied electrical field. It is usually used in molecular biology as a way of introducing some substance into a cell ...The process of introducing foreign DNAs into eukaryotic cells is known as transfection...
The success of the electroporation depends greatly on the purity of the plasmid solution, especially on its salt content. Impure solutions might cause a small explosion..."
Electroporation-based DNA delivery systems, brought to you by the folks at Karolinska University Hospital, the same place that did the "let's give them so much riba they need transfusions" study.
They get to try some cool stuff in Sweden.
"...a significant increase in the electrical conductivity and permeability of the cell plasma membrane caused by an externally applied electrical field. It is usually used in molecular biology as a way of introducing some substance into a cell ...The process of introducing foreign DNAs into eukaryotic cells is known as transfection...
The success of the electroporation depends greatly on the purity of the plasmid solution, especially on its salt content. Impure solutions might cause a small explosion..."
Electroporation-based DNA delivery systems, brought to you by the folks at Karolinska University Hospital, the same place that did the "let's give them so much riba they need transfusions" study.
They get to try some cool stuff in Sweden.
It would be a dream come true if a vaccination could clear this virus. Thanks for posting,
dointime
dointime
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
